FoxCross PTA Catheter

COMPANY	Abbott Vascular
PHONE	(800) 227-9902
WEB	www.abbottvascular.com

KEY FEATURES

- A highly deliverable balloon dilatation catheter for patients with PAD
- Proprietary Jetcoat coating that allows for smooth device movement and enhanced deliverability
- Streamlined tip and crossing profile for accessing and treating challenging lesions
- Dual-lumen shaft with large, crescent-shaped contrast lumen for rapid inflation/deflation

The FoxCross PTA catheter (Abbott Vascular, Santa Clara, CA) is a highly deliverable next-generation 0.035-inch balloon dilatation catheter designed to optimize the treatment of patients with peripheral artery disease during angioplasty procedures by incorporating the latest technological advancements.

"A highly deliverable balloon dilatation catheter is key to successful patient outcomes. If the balloon does not cross the blockage smoothly and reliably, the procedure can take longer and may be prone to complications, as well as additional costs," said Joseph A. R. Cardenas, MD, FACC, medical director of the cardiac catheterization laboratory at the Yuma Regional Medical Center in Yuma, Arizona. "The FoxCross system offers superb crossability and impressive deflation times, making it suitable for challenging lesions."

The system is available in a wide variety of diameters (3–14 mm), balloon lengths (20–120 mm), and catheter lengths (50, 80, and 135 cm) on an over-the-wire delivery platform.

OA-1500

COMPANY	Total Vein Systems
PHONE	(888) 868-8346
WEB	www.totalvein.com

KEY FEATURES

- Three-year full warranty
- Five-year warranty on the diodes
- 980 nanometers
- 15 watts

The Optical Advantage 1500 by Total Vein Systems (Houston, TX) is a class IV, solid-state systems that provides 980 nanometers of laser energy up to 15 watts in pulse or continuous wave modes. The OA-1500 also comes with a fiber hand piece to be used to treat vascular lesions and for minor surgical procedures. Weighing just 12 pounds, the OA-1500 has a small footprint of 12.5 X 9.5 X 6.5 inches.

"The low cost of this laser makes the decision to add laser technology or to add a second system to a physicians practice less difficult particularly in today's financial environment," co-owner David Centanni said. "In addition, the OA-1500 uses a standard SMA 905 universal connector, which makes it compatible with a variety of fibers, including reusable fibers."

Cardiva Catalyst III

COMPANY	Cardiva Medical, Inc.
PHONE	(650) 964-8900
WEB	www.cardivamedical.com

KEY FEATURES

- Protamine sulfate coating
- For use in heparinized patients
- For use with 5-, 6-, or 7-F introducer sheaths
- Supports the body's natural healing process

Cardiva Medical, Inc. (Mountain View, CA) has received clearance from the US Food and Drug Administration for its latest technology, the Cardiva Catalyst III, which is considered the first drug-coated vessel closure device in the market. Built upon its predecessor, the Cardiva Catalyst III is coated with protamine sulfate, a drug that neutralizes heparin. The Cardiva Catalyst III is indicated for use in heparinized patients undergoing diagnostic and/or interventional femoral artery catheterization procedures using 5-, 6-, or 7-F introducer sheaths. Local heparin reversal by the Cardiva Catalyst III facilitates quick and efficient vessel closure as an adjunct to manual compression in patients receiving anticoagulation with heparin, the company stated. Cardiva Catalyst III's protamine coating contacts the tissue tract from the arteriotomy site to the point of percutaneous entry in the skin.

Option Inferior Vena Cava Filter

COMPANY	Angiotech Pharmaceuticals, Inc.
PHONE	(604) 221-7676
WEB	www.angiotech.com

KEY FEATURES

- Permanent and retrievable indications
- Low-profile delivery system
- Self-centering filter

Angiotech Pharmaceuticals, Inc. (Vancouver, British Columbia, Canada) has been granted 510(k) clearance from the US Food and Drug Administration for the Option Inferior Vena Cava (IVC) filter for use in both permanent and retrievable indications. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC filter, which it obtained in a license agreement with privately held Rex Medical, LP (Conshohocken, PA), as previously announced in March 2008.

According to the company, the Option IVC filter is used for the prevention of recurrent pulmonary embolism (PE). The device is implanted into the body's inferior vena cava to prevent PE. Option is specifically designed for use as both a permanent or temporary implant (in temporary, or retrievable, indications, a physician may later perform a second surgical procedure to remove the Option IVC Filter if necessary or where mandated clinically. The nitinol Option IVC Filter, with a low-profile delivery system, is designed with struts that direct clot volume into the center of the vessel for maximum dissolution and preservation of blood flow, allowing for capture of clinically significant clot and protection against PE. The self-centering filter facilitates optimal positioning and stability within the inferior vena cava.

Xcela PICC

COMPANY	Navilyst Medical
PHONE	(877) 658-7990
WEB	www.navilystmedical.com

KEY FEATURES

- Easy to place and simple to maintain
- PASV technology design automatically resists backflow, reducing blood reflux that can lead to catheter-related complications
- Features an array of kit configurations, Exact-Length measurement system, trimmable catheter tip, enhanced radiopacity, and reverse taper extrusion

Navilyst Medical (Marlborough, MA) announced that it has combined their Pressure-Activated Safety Valve (PASV) technology with their Xcela Power Injectable Catheter technology to create the Xcela peripherally inserted central catheter (PICC) with PASV technology. The new PICC is designed to offer a high degree of safety, ease, and confidence in patient care. According to the company, the PASV technology design automatically resists backflow, reducing blood reflux that can lead to catheter-related complications. In addition, the Xcela PICC with PASV technology is easy to place and simple to maintain.

Ease of placement with the PICC is possible with its broad array of kit configurations, Exact-Length measurement system, trimmable catheter tip, enhanced radiopacity, and reverse taper extrusion. The PICC's simplified care and maintenance routine features alcohol-resistant material, clampless extension legs, the freedom to choose the institution's preferred needleless connector, and minimum weekly saline flush, which can limit complications and cost associated with heparin use.

Ziehm Vision RFD

COMPANY	Ziehm Imaging, Inc.
PHONE	(951) 781-2020
WEB	www.ziehm.com

KEY FEATURES

- 30- X 30-cm flat panel detector provides improved dynamic range and increased field of view
- Pulse technology at up to 25 frames per second provides sharp, high-contrast images
- Larger C-arm opening and 165° orbital rotation allows better access to the patient

Ziehm Imaging, Inc. (Orlando, FL) recently announced it has received 510(k) clearance from the US Food and Drug Administration for its mobile fluoroscopic imaging system, the Ziehm Vision RFD. Designed for procedures common in endovascular surgery, interventional radiology, and interventional cardiology, the Ziehm Vision RFD mobile C-arm combines innovative flat-panel technology with object-detected, dose-control software and specially designed anatomical programs for fully digital, distortion-free imaging. The Ziehm Vision RFD has pulse technology at up to 25 frames per second, which provides sharp, high-contrast images of vascular, bone, and soft tissue structures. According to the company, the Ziehm Vision RFD's advanced design and the flat-panel detector's increased field of view provide physicians with a wide range of benefits; the 30- X 30-cm flat-panel detector with 1,500- X 1,500-pixel resolution provide extended dynamic range and 49% greater anatomical viewing when compared to 12-inch image intensifier systems. "Using fully digital technology, we are setting standards for C-arms in terms of image quality and patient care," comments Klaus Hörndler, chief executive officer of Ziehm Imaging. "Our aim is to evolve x-ray–based imaging methods consistently so that we can provide physicians with the best possible technology to enable enhanced treatments." ■